Top Skin Biopsy Companies

Global Skin Biopsy Market size was valued at USD 31.9 billion in 2023 and is poised to grow from USD 35.3 billion in 2024 to USD 80.29 billion by 2032, growing at a CAGR of 10.8% during the forecast period (2025-2032).

In the global skin biopsy market major companies like Integra Lifesciences, Becton, Dickinson and Company, and Innovia Medical are top companies of the market having their advanced biopsy technologies. Additionally, emerging players such as Proscia are presenting innovative AI-powered solutions like DermAI for improved biopsy analysis. This shows that the market is competitive in nature. Overall, there are some dominant players in the market but smaller companies are also competing at the same level and are together contributing to market growth. 'Becton, Dickinson and Company (USA) ', 'Cardinal Health (USA) ', 'Boston Scientific Corporation (USA) ', 'Cook Medical (USA) ', 'Hologic, Inc. (USA) ', 'Leica Biosystems Nussloch GmbH (Germany) ', 'Danaher Corporation (USA) ', 'Integra LifeSciences (USA) ', 'Innovia Medical (USA) ', 'DTR Medical Ltd (UK) ', 'Gallini Srl (Italy) ', 'KAI Group (Japan) ', 'AccuTec, Inc. (USA) ', 'Biomarker Technologies (China) ', 'Vernacare (UK) ', 'Freenome Holdings, Inc. (USA) ', 'Biodesix (USA) ', 'Exact Sciences Corporation (USA) ', 'GRAIL, Inc. (USA) ', 'GenMark Diagnostics (USA) ', '​​In February 2023, SynapsDx introduced a new diagnostic test for Alzheimer's disease based on skin samples. The test uses three biomarkers to detect Alzheimer's and distinguish it from other forms of dementia. It primarily relies on morphometric imaging, which measures cell growth in skin samples from patients. In Alzheimer's patients, there are fewer large aggregates found in the skin cells.', 'In May 2023, Argon Medical Devices, Inc. introduced the SuperCore Advantage Semi-Automatic Biopsy instrument, expanding its range of soft tissue biopsy products in the United States.', 'In April 2023, GE Healthcare unveiled the bkActiv system designed for surgical applications. This system offers surgeons advanced ultrasound imaging capabilities to enhance visualization during surgical procedures.', 'In September 2023, Dxcover Limited expanded its executive team to enhance the development of its multi-cancer liquid biopsy platform and in February 2023, Dxcover Limited secured $11.9 million in Series A funding and grants to progress its liquid biopsy platform for early-stage cancer detection.'

AI-powered software is helping pathologists by analyzing results of the biopsy procedure in a faster way and more correctly. This technology helps in making the diagnostic process smoother, lowering delays, and making the market more effective. AI is expert in digitizing so adapting the same path here by making it easier to digitize pathology slides and allowing pathologists to refer with experts remotely. This means pathologists can connect online and can share any image online to get opinions from specialists, even in those areas where access to pathology services is very less. This helps connect with specialized expertise easily and drives growth in the global biopsy market.

Increasing Utilization of Integrated Biopsy Methods in Healthcare: In the healthcare industry, there's a growing trend towards combined biopsy techniques to improve diagnostic accuracy and patient outcomes. For acquiring more detailed information from tissue samples, the hospitals like Texas Children's Hospital and United Hospital Central West Virginia are combining different diagnostic processes like image-guided biopsies, endoscopic procedures, and molecular analysis. This technology is helping healthcare workers to understand pathology better, leading to more accurate diagnoses and treatment plans. The integrated biopsy procedures are increasingly adopted by clinicians to improve diagnostic capabilities and patient care. Therefore, there is a predictable rise in the demand for biopsy devices at a faster rate.

The dominating region in the global skin biopsy market is North America, which holds a significant market share. North America is expected to lead the global biopsy market from 2024 to 2031 in which United States is playing a huge role. The market share of this region in 2023 was about 40.2% and is expected to keep dominating. The growth in North America is further propelled by many factors including new and improved technology for early stages detection, production of the new kits for earlier diagnosis and increasing demand for less invasive procedures. As cancer cases are rising and government is taking initiatives for early diagnosis is also contributing to the growth of this region. For instance, in June 2023, the National Institute of Government conducted a study on 1308 biopsy proceedings. The study displayed that most of the patients were youths and there were more males than females. Approximately 12.9% of the biopsies were performed on pediatric patients, and most of the patients had only one biopsy. However, there are many people who perform biopsies, primarily for the diagnostic reasons. The patients performing biopsies were mostly 12 years old. Furthermore, the minimally invasive biopsy methods is expected to rise due to its demand among people. The technologies and new products like biopsy guiding systems, needle-based biopsy guns, and vacuum-assisted devices are anticipated to become widespread among the people during the forecasted period. Due to the prevalence of these trends, the market is expected to grow significantly.